SHR-1501
Unknown / undisclosed
Evidence outlook · registrational
Non-Muscle Invasive Bladder Cancer: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2029-12.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other IL-15 drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Non-Muscle Invasive Bladder Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| SHR-1501: this drug | Phase 3 | Undisclosed | IL-15 | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| TAR-210 | Phase 3 | Intravesical Drug Delivery System (erdafitinib) | — | not yet graded | No reviewed efficacy summary in this indication | |
| TARA-002 | Phase 3 | Bacterial immunotherapy | Innate and adaptive immune activation (inactivated Streptococcus pyogenes) | not yet graded | No reviewed efficacy summary in this indication | |
| GIA632 | Phase 2(overall) | Monoclonal antibody | IL-15 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| PF-08052667 | Phase 1 | Antibody–drug conjugate | Integrin beta-6 (ITGB6) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow SHR-1501 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.